No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BDX Becton Dickinson & Co
- 229.110
- +4.170+1.85%
Close Jul 12 16:00 ET
- 228.310
- -0.800-0.35%
Post 18:11 ET
66.21BMarket Cap50.80P/E (TTM)
230.340High224.630Low2.22MVolume225.500Open224.940Pre Close507.79MTurnover0.77%Turnover Ratio46.38P/E (Static)289.01MShares282.89552wk High2.58P/B66.06BFloat Cap218.75052wk Low3.72Dividend TTM288.35MShs Float282.895Historical High1.62%Div YieldTTM2.54%Amplitude13.014Historical Low228.677Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Becton Dickinson Warns of Blood Culture Product Delays
UnitedHealth, Edwards Lifesciences, First Citizens Bank And More: CNBC's 'Final Trades'
Jim Lebenthal of Cerity Partners hyped UnitedHealth Group Incorporated (NYSE:UNH) as a "solid" healthcare company in the latest edition of CNBC's "Halftime Report Final Trades." On July 9, Cantor
Wells Fargo Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $290
Wells Fargo analyst Larry Biegelsen maintains $Becton Dickinson & Co(BDX.US)$ with a buy rating, and maintains the target price at $290.According to TipRanks data, the analyst has a success rate of 58
Express News | Citigroup Maintains Neutral on Becton Dickinson, Lowers Price Target to $255
Becton Dickinson's Stock Bounces as FDA Addresses Supply Issue With Blood-culture Vials
By Tomi Kilgore Medical-supply company looks to fill gaps as former supplier restarts production of vials Shares of Becton Dickinson & Co. bounced back Wednesday toward their first gain in seven
Express News | BD Committed To Global Health; Mitigating Blood Culture Vial Supplier Issue With FDA Collaboration, Rapid Production, And Restarting Glass Vial Production; Manual Allocation To Prioritize Clinical Needs; No Material Financial Impact Expected
Comments
$Becton Dickinson & Co(BDX.US$ GAME OVER stock.
Despite a dip in earnings, Becton Dickinson's high P/E ratio persists due to anticipated robust future growth, outpacing the broader market. Investors' confidence in the company's future earnings is high, indicating the share price is unlikely to drop significantly soon.
$Becton Dickinson & Co(BDX.US$ BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
2
Dr. Silverman's extensive experience and zeal for innovation, evidence generation, clinical development, medical safety, and compliance is predicted to boost BD's innovation pipeline and foster improved, personalized care.
Market sentiment towards Becton, Dickinson and Company shows no major shift in the past year. However, the rise in total shareholder return hints at a growing positivity.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg